Nuvation Bio Inc.

Equities

NUVB

US67080N1019

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-04-17 pm EDT			5-day change	1st Jan Change
2.69 ^USD	-4.27%		-11.80%	+78.15%

Apr. 17	RBC Raises Price Target on Nuvation Bio to $5 From $4, Keeps Outperform, Speculative Risk	MT
Apr. 10	Nuvation Bio Closes Acquisition of AnHeart Therapeutics	MT

Nuvation Bio Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 04, 2022 at 04:05 pm EDT

Nuvation Bio Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 34.86 million compared to USD 19.33 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.09 a year ago.
For the six months, net loss was USD 56.15 million compared to USD 39.74 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.21 a year ago.

Latest news about Nuvation Bio Inc.

RBC Raises Price Target on Nuvation Bio to $5 From $4, Keeps Outperform, Speculative Risk	Apr. 17	MT
Nuvation Bio Closes Acquisition of AnHeart Therapeutics	Apr. 10	MT
Nuvation Bio Inc. Announces Appointment of Directors	Apr. 10	CI
Nuvation Bio Inc. completed the acquisition of AnHeart Therapeutics Ltd	Apr. 08	CI
HC Wainwright Adjusts Nuvation Bio's Price Target to $8 From $5, Maintains Buy Rating	Mar. 28	MT
Nuvation Bio Inc. Appoints Colleen Sjogren as Chief Commercial Officer	Mar. 28	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Nuvation Bio Shares Jump After Jefferies Upgrade	Mar. 27	MT
Top Premarket Gainers	Mar. 27	MT
Jefferies Upgrades Nuvation Bio to Buy From Hold, Adjusts Price Target to $10 From $1.40	Mar. 27	MT
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
BTIG Upgrades Nuvation Bio to Buy From Neutral, Price Target is $5	Mar. 26	MT
Nuvation Bio Agrees to Acquire AnHeart Therapeutics in All-Stock Deal -- Shares Fall	Mar. 25	MT
Nuvation Bio Inc. entered into an Agreement and Plan of Merger to acquire AnHeart Therapeutics Ltd.	Mar. 24	CI
Nuvation Bio Doses First Patient in Phase 1/2 Study of Advanced Solid Tumor Treatment	Mar. 14	MT
Nuvation Bio Inc. Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors	Mar. 14	CI
H.C. Wainwright Raises Price Target on Nuvation Bio to $5 From $4.50, Maintains Buy Rating	Mar. 07	MT
Nuvation Bio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Nuvation Bio Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Nuvation Bio Receives US FDA Clearance for Investigational New Drug Application for NUV-1511	Jan. 08	MT
Nuvation Bio Gets New Drug Application Clearance From FDA for Solid Tumor Treatment	Jan. 08	DJ
Nuvation Bio Inc. Announces Appointment of Robert Mashal to Its Board of Directors	Jan. 08	CI
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors	Jan. 08	CI
Nuvation Bio Inc. Announces Resignation of Oleg Nodelman from Board of Directors	Dec. 14	CI
Nuvation Bio Inc. Appoints Moses Makunje as Principal Accounting Officer and Principal Financial Officer	Nov. 27	CI

Chart Nuvation Bio Inc.

Duration

Period

More charts

Company Profile

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.69 USD

Average target price

6.6 USD

Spread / Average Target

+145.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NUVATION BIO INC.	+78.15%	738M
IQVIA HOLDINGS INC.	-1.78%	41.71B
LONZA GROUP AG	+47.70%	41.56B
MODERNA, INC.	+4.01%	39.74B
CELLTRION, INC.	-15.14%	25.61B
ICON PUBLIC LIMITED COMPANY	+3.16%	24.26B
ALNYLAM PHARMACEUTICALS, INC.	-24.08%	18.55B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.93B
MEDPACE HOLDINGS, INC.	+24.76%	11.93B
UNITED THERAPEUTICS CORPORATION	+7.01%	10.91B

Other Biotechnology & Medical Research